InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES string
ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl
grade
analytical standard
packaging
ampule of 250 mg
manufacturer/tradename
Chem Service, Inc. PS-694
Gene Information
rat ... Ar(24208)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lawrence S Kirschner
Trends in endocrinology and metabolism: TEM, 23(7), 343-350 (2012-05-26)
Adrenocortical carcinoma (ACC) is a rare cancer for which few treatment options have been available. Currently, the best available treatment involves combination chemotherapy with the adrenolytic drug mitotane, although the response rate remains modest. Over the past 10 years there
A Redlich et al.
Klinische Padiatrie, 224(6), 366-371 (2012-11-13)
Adrenocortical cancer (ACC) in childhood is a rare disease with poor prognosis. Complete surgical resection, systemic chemotherapy, and mitotane therapy are important curative treatment options for patients with advanced-stage tumors. Since 1997, pediatric ACC patients in Germany have been treated
Ilse G C Hermsen et al.
European journal of endocrinology, 169(1), 51-58 (2013-04-16)
Adrenocortical carcinoma (ACC) is a rare disease with a poor prognosis and limited therapeutic options. Mitotane is considered the standard first-line therapy with only 30% of the patients showing objective tumour response. Defining predictive factors for response is therefore of
Liana Tripto-Shkolnik et al.
The Journal of clinical endocrinology and metabolism, 98(2), 443-447 (2013-01-01)
Adrenocortical carcinoma (ACC) affects patients in a broad age group, including young women. Mitotane, an adrenolytic agent, is the mainstay of treatment after surgical removal of the tumor. There is extreme paucity of information regarding the effect of mitotane on
Akira Takeshita et al.
The Journal of endocrinology, 216(3), 297-305 (2012-11-28)
Adrenocortical carcinoma (ACC) is a rare disease with an extremely poor prognosis. Mitotane alone or in combination with other cytotoxic drugs is a common therapeutic option for ACC. In addition to its adrenolytic function, mitotane has been known for decades
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service